Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05904470 · ClinicalTrials.gov registry record · Phase 2

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

A Phase 2 study of Hepatitis C and Hepatitis C, Chronic, sponsored by Atea Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
275
Enrollment target
20
Study locations

NCT05904470 is a Phase 2 study of Hepatitis C and Hepatitis C, Chronic that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 275 participants, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05904470, a Phase 2 study of Hepatitis C and Hepatitis C, Chronic, has completed, sponsored by Atea Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
275 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

Conditions Studied

Hepatitis C Hepatitis C, Chronic HCV Chronic Hepatitis C Virus Hepatic Cirrhosis

Interventions

  • DRUG Bemnifosbuvir
  • DRUG Ruzasvir

Study Locations (20)

São Paulo

  • Atea Study Site - Botucatu
  • Atea Study Site - Ijuí
  • Atea Study Site - São José do Rio Preto
  • Atea Study Site - São Paulo
  • Atea Study Site - São Paulo
  • Atea Study Site - Sorocaba

Rio Grande do Sul

  • Atea Study Site - Porto Alegre
  • Atea Study Site - Porto Alegre

Gujarat

  • Atea Study Site - Rajkot
  • Atea Study Site - Surat

Texas

  • Atea Study Site - San Antonio

Amazonas

  • Atea Study Site - Manaus

Estado de Bahia

  • Atea Study Site - Salvador

Federal District

  • Atea Study Site - Brasília

Rio Do Janeiro

  • Atea Study Site - Rio de Janeiro

Trial Details

FieldValue
Enrollment Target 275 participants
Start Date 2023-05-30
Est. Completion 2025-01-28
Phase Phase 2

Sponsor

Atea Pharmaceuticals

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05904470

The ClinicalTrials.gov registry entry for NCT05904470 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (85% lower). The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Bemnifosbuvir is the first listed.

NCT05904470 reports 20 study locations spanning 13 distinct geographic areas - top geographies include São Paulo, Rio Grande do Sul, Gujarat.

Frequently Asked Questions

What is clinical trial NCT05904470 about?

NCT05904470 is a clinical study titled "A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV". This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

What is the current status of trial NCT05904470?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2023-05-30. Estimated completion is 2025-01-28.

What conditions does trial NCT05904470 study?

This clinical trial studies the following conditions: Hepatitis C, Hepatitis C, Chronic, HCV, Chronic Hepatitis C Virus, Hepatic Cirrhosis.

What interventions are being tested in trial NCT05904470?

The interventions under investigation include: Bemnifosbuvir (DRUG), Ruzasvir (DRUG).

Who is sponsoring clinical trial NCT05904470?

This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05904470 being conducted?

This trial has 20 study locations across Texas, Amazonas, Estado de Bahia, Federal District, Rio Do Janeiro. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C

All registered trials for this condition

Hepatitis C, Chronic

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.